Clinical trial NCT06293131: Median Effective Dose of Ciprofol-Assisted Sedation for Elderly Patients Undergoing Knee Arthroplasty
Official title: Median Effective Dose of Ciprofol-Assisted Sedation for Elderly Patients Undergoing Knee Arthroplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Sedation
ED50
Knee Arthroplasty
Lead sponsor: Second Hospital of Shanxi Medical University
Sponsor class: OTHER
First posted: 2024-03-05
Enrollment: 70
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: OTHER

Brief summary: Regional anesthesia is a common clinical anesthesia method, and regional anesthesia-assisted sedation play a central role in promoting patient comfort and relieving anxiety. With increasing age, elderly people experience changes in pharmacokinetics and pharmacodynamics and increased drug sensitivity. Ciprofol has advantages in adverse events such as hypotension and respiratory depression. There are fewer studies on the recommended dosage of ciprofol-assisted sedation for intrathecal anesthesia in elderly patients. The aim of study is to identify the median effective dose(ED50) of ciprofol-assisted sedation in elderly patients undergoing spinal anesthesia

Detailed description: Select the patients who received knee arthroplasty in the Second Hospital of Shanxi Medical University. The patients received a loading dosage of 0.05mg/kg of ciprofol to begin sedation following the completion of intravertebral anesthesia, and the maintenance dose is calculated using the sequential method. Based on the relevant literature and pilot study, 0.2 mg·kg-1·h-1 is selected as initial test dose with a dose gradient of 0.02 mg·kg-1·h-1. The Modified Alertness Sedation Score (MOAA/S ) scores and the bispectral index (BIS) were recorded for patients before administration (T0), 5 min after administration (T1), 10 min after administration (T2), 20 min after administration (T3), 30 min after administration (T4), 45 min after administration (T5), and 60min after administration (T6). If the first patient had ≥ 4 time points with MOAA/A score ≤3 and BIS\<85 from T0-T6, the sedation was regarded as satisfactory, then the next patient 's dose of ciprofol was reduced by one level. On the contrary, if the patient's MOAA/S score and BIS at T0-T6 had less than 4 points of MOAA/S ≤3 points and BIS \<85, it was regarded as unsatisfactory sedation. The next patient's dose of ciprofol was increased by one level. After 8 crossovers, the trial was terminated. At the same time, the change of vital signs and adverse reactions before and after administration were recorded

Eligibility criteria: Inclusion Criteria:

* Age ≥ 65 years
* ASA grade I\~III
* BMI 18\~30 kg/m2

Exclusion Criteria:

* Contraindications to intrathecal anesthesia
* Suffering from severe psychiatric or neurologic disorders or taking sedative drugs within the last 3 months
* Difficult airway or having respiratory diseases such as upper airway obstruction
* Severe cardiovascular system diseases
* Severe hepatic or renal dysfunction
* Allergy or contraindication to propofol and its drug-related components
* Patient Prefusal

Primary outcomes:
measure: Modified Alertness Sedation Score (MOAA/S)
timeFrame: 24 hours
measure: Bispectral index (BIS)
timeFrame: 24 hours
Secondary outcomes:
measure: systolic blood pressure （SBP）
timeFrame: 24 hours
measure: diastolic blood pressure（DBP）
timeFrame: 24 hours
measure: heart rate (HR)
timeFrame: 24 hours
measure: pulse oxygen saturation（SpO2）
timeFrame: 24 hours
Other outcomes:
measure: Occurrence of Sedation-related adverse events
timeFrame: 72 hours
Locations:
city: Taiyuan
country: China
facility: Second Hospital of Shanxi Medical University
state: Shanxi
Study officials:
References: